Johnson & Johnson (JNJ)

Johnson & Johnson’s first quarter results reflected a steady performance, with the company surpassing Wall Street’s revenue and adjusted profit expectations. Management credited the diversified portfolio across innovative medicine and MedTech as key to navigating industry challenges, particularly the loss of market exclusivity for STELARA, a major pharmaceutical product. CEO Joaquin Duato highlighted, “No other healthcare company has delivered growth through the first year of Lucin exclusivity for a multibillion-dollar product...and yet, that is exactly what we are doing.” The company’s ability to offset biosimilar competition with double-digit growth from eleven key brands and strong operational execution was a central theme of the quarter.

The Democratic lawmakers alleged that pharmaceutical companies avoided paying U.S. tax bills by shifting their profits to offshore subsidiaries in jurisdictions with significantly lower tax rates, such as Ireland and Bermuda, according to CNBC.

Johnson & Johnson (NYSE:JNJ) is a top dividend stock with a 3.32% yield, strong profitability, and a reliable payout history, making it a solid choice for income investors.

Steady growth and dividend increases over decades can make investors remarkably wealthy.

With earnings season coming to an end, investors are looking for new catalysts; here are three blue-chip companies with strong analyst support

Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.

Johnson & Johnson shared positive ASCO 2025 results, including improved survival and remission in prostate and multiple myeloma patients.

These stocks are ready for a summer surge.

For long-term investors looking for both stability and innovation in the healthcare space, JNJ is a rare combination of both.

Michael Mahoney's grandfather was a cardiac surgeon — so his first career plan was to become a doctor. Mahoney didn't give up — he adjusted.

Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design.

Activist investor Dan Loeb's Third Point LLC acquired a significant stake in consumer health company Kenvue Inc. in Q1 2025.

Johnson & Johnson (NYSE:JNJ) offers a strong dividend yield, consistent growth, and solid profitability, making it a compelling choice for income investors.